Efficacy of a Dexamethasone Implant for the Treatment of Refractory Cystoid Macular Oedema in Non-Infectious Uveitis

被引:11
作者
Breitbach, M. [1 ]
Rack, D. [1 ]
Dietzel, M. [1 ]
Heinz, C. [2 ]
Heiligenhaus, A. [2 ]
机构
[1] St Franziskus Hosp, Augenabt, D-48145 Munster, Germany
[2] Univ Diusburg Essen, Univ Augenklin Essen, Essen, Germany
关键词
intraocular inflammation; macular oedema; dexamethasone implant; corticosteroid; ozurdex (R); uveitis; INTRAVITREAL TRIAMCINOLONE; ACETAZOLAMIDE; DISEASE; INFLAMMATION; FREQUENCY;
D O I
10.1055/s-0042-102058
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the efficacy of an intravitreal dexamethasone implant (Ozurdex (R)) in patients with cystoidmacular oedema (CME) suffering from non-infectious uveitis. Methods: Monocentric, retrospective, single-arm analysis in 49 patients (59 implanted eyes) with inactive uveitis, in whom CME had been unresponsive to corticosteroids and/or immunosuppressants and systemic acetazolamide, and who received a dexamethasone implant. Patients were followed up at 6, 12 and 24 weeks after unilateral (n = 39)/bilateral (n = 10) implantation. The primary outcome measure was central foveal thickness (CFT), as measured by Spectralis optical coherence tomography (OCT); secondary outcome measures were improvement in best-corrected visual acuity (BCVA), laser flare photometry and safety measures, including intraocular pressure (IOP) and cataract progression. Results: At 6, 12 and 24 weeks, mean CFT was reduced (>= 20%) in 68, 44 and 45% and BCVA improved (>= 2 lines) in 47, 40 and 26%, respectively, as compared to baseline. At 6, 12 and 24 weeks, significant flare reduction was observed in 70, 41, and 42%, respectively. Cumulative cataract progression was observed in 12, 18 and 31% at 6, 12 and 24 weeks, respectively. IOP >= 22 mm Hg was noted in 5% at baseline and in 21, 3, and 0% at 6, 12 and 24 weeks, respectively. Conclusions: In uveitis patients with CME refractory to systemic anti-inflammatory drugs, the dexamethasone implant improves CME transiently. However, IOP increase and cataract progression are common side effects.
引用
收藏
页码:601 / 605
页数:5
相关论文
共 50 条
[21]   Risk factors for cystoid macular oedema in patients with uveitis [J].
B van Kooij ;
K Probst ;
R Fijnheer ;
M Roest ;
W de Loos ;
A Rothova .
Eye, 2008, 22 :256-260
[22]   Intravitreal diclofenac for treatment of refractory uveitis-associated cystoid macular oedema: A before and after clinical study [J].
Kianersi, Farzan ;
Rezaeian-Ramsheh, Abdolreza ;
Pourazizi, Mohsen ;
Kianersi, Hamidreza .
ACTA OPHTHALMOLOGICA, 2018, 96 (03) :E355-E360
[23]   Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis [J].
Tosi, G. M. ;
Sota, J. ;
Vitale, A. ;
Rigante, D. ;
Emmi, G. ;
Lopalco, G. ;
Guerriero, S. ;
Orlando, I. ;
Iannone, F. ;
Frediani, B. ;
Angotti, R. ;
Messina, M. ;
Galeazzi, M. ;
Vannozzi, L. ;
Cantarini, L. ;
Fabiani, C. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) :680-683
[24]   Risk factors for cystoid macular oedema in patients with uveitis [J].
van Kooij, B. ;
Probst, K. ;
Fijnheer, R. ;
Roest, M. ;
de Loos, W. ;
Rothova, A. .
EYE, 2008, 22 (02) :256-260
[25]   Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies [J].
Hiyama, Tomona ;
Harada, Yosuke ;
Kiuchi, Yoshiaki .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (04) :951-958
[26]   PROSPECTIVE EVALUATION OF A SUSTAINED-RELEASE DEXAMETHASONE INTRAVITREAL IMPLANT FOR CYSTOID MACULAR EDEMA IN QUIESCENT UVEITIS [J].
Khurana, Rahul N. ;
Bansal, Alok S. ;
Chang, Louis K. ;
Palmer, James D. ;
Wu, Chengqing ;
Wieland, Mark R. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (09) :1692-1699
[27]   Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis [J].
Maca, Saskia M. ;
Abela-Formanek, Claudette ;
Kiss, Christopher G. ;
Sacu, Stefan G. ;
Benesch, Thomas ;
Barisani-Asenbauer, Talin .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 37 (04) :389-396
[28]   Treatment of chronic non-infectious uveitis and scleritis [J].
Daniele, Rossi C. ;
Camillo, Ribi ;
Yan, Guex-Crosier .
SWISS MEDICAL WEEKLY, 2019, 149
[29]   Therapeutic options for the treatment of non-infectious uveitis [J].
Knickelbein, Jared E. ;
Jaworski, Laurence ;
Hasan, Jesia ;
Kaushal, Padmini ;
Sen, H. Nida ;
Nussenblatt, Robert B. .
EXPERT REVIEW OF OPHTHALMOLOGY, 2015, 10 (04) :359-373
[30]   Rituximab in the Treatment of Non-Infectious Uveitis: A Review [J].
Cao, Haixing ;
Ma, Xiang .
JOURNAL OF INFLAMMATION RESEARCH, 2024, 17 :6765-6780